Zelboraf and Fall - a phase IV clinical study of FDA data

Summary:

Fall is reported as a side effect among people who take Zelboraf (vemurafenib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Cotellic, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Fall when taking Zelboraf. It is created by eHealthMe based on reports of 8,381 people who have side effects when taking Zelboraf from the FDA, and is updated regularly.

What is Zelboraf?

Zelboraf has active ingredients of vemurafenib. eHealthMe is studying from 8,392 Zelboraf users. Check the latest studies of Zelboraf.

What is Fall?

Fall is found to be associated with 3,277 drugs and 3,757 conditions by eHealthMe. Check the latest studies of Fall.

On Jun, 19, 2026

8,381 people reported to have side effects when taking Zelboraf.
Among them, 53 people (0.63%) have Fall.

Among these 53 people:

How long have people been on Zelboraf when they have Fall? *

What is the gender of people who have Fall when taking Zelboraf? *

female: 40.43 %
male: 59.57 %

What is the age of people who have Fall when taking Zelboraf? *

What are other drugs people take besides Zelboraf? *

Cotellic: 15 people, 28.30%
Cladribine: 12 people, 22.64%
Amlodipine: 8 people, 15.09%
Paracetamol: 6 people, 11.32%
Movicol: 6 people, 11.32%
Cotrim: 6 people, 11.32%
Tylenol: 4 people, 7.55%
Depakote: 3 people, 5.66%
Pantoprazole: 3 people, 5.66%
Fentanyl Transdermal System: 3 people, 5.66%

What are other side effects people have besides Fall? *

Weakness: 25 people, 47.17%
Fatigue (feeling of tiredness): 25 people, 47.17%
Rashes (redness): 25 people, 47.17%
Itching: 19 people, 35.85%
Diarrhea: 18 people, 33.96%
Femur Fracture: 15 people, 28.30%
Anaemia (lack of blood): 15 people, 28.30%
Osteoporosis (bones weak and more likely to break): 14 people, 26.42%
Enlarged Prostate: 13 people, 24.53%
Overgrowth Bacterial (extra growth due to bacteria): 13 people, 24.53%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 21 people, 39.62%
Hairy Cell Leukaemia (a type of blood cancer): 13 people, 24.53%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 10 people, 18.87%
Pain: 10 people, 18.87%
High Blood Pressure: 10 people, 18.87%
Metastases To Central Nervous System (cancer spreads to central nervous system): 8 people, 15.09%
Constipation: 7 people, 13.21%
Thrombosis (formation of a blood clot inside a blood vessel): 6 people, 11.32%
Neoplasm Malignant (cancer tumour): 6 people, 11.32%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 7.55%

* Approximation only. Some reports may have incomplete information.

Do you take Zelboraf and have Fall?

- Check whether Fall is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zelboraf:

Zelboraf (8,392 reports)

Fall treatments and more:

Fall (403,513 reports)

Browse all side effects of Zelboraf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fall:

Fall (3,277 drugs)

Browse all the conditions that are associated with Fall:

Fall (3,757 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vemurafenib (the active ingredients of Zelboraf) and Zelboraf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.